Supplementary Figure 5, RAS expression in hematopoietic cancer cell lines and human pediatric AML samples. (A) NRAS and KRAS expression in 175 human hematopoietic cancer cell lines with NRAS mutations (n = 26), KRAS mutations (n = 21), or no RAS mutation (n = 128). (B) NRAS and KRAS expression in human samples with normal CD34+ progenitors (n = 4), AML with no RAS mutation (n = 74), and AML with NRAS mutation (N = 30). NRAS was higher expressed in AML samples as compared to normal CD34+ progenitors (left panel, p=0.0457)